NEW CANAAN, CT--(Marketwire - January 22, 2008) - Marshall Edwards, Inc. (NASDAQ: MSHL) announced today that its triphendiol (previously known as NV-196) has been granted orphan drug status by the U.S. Food and Drug Administration (FDA) for the treatment of pancreatic cancer and for the treatment of cholangiocarcinoma, or bile duct cancer.
